Allogene Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALLO Nasdaq 2830 www.allogene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allogene Therapeutics, Inc.

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Mar 15th, 2025 12:18 pm
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... - Mar 14th, 2025 7:00 pm
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil - Mar 14th, 2025 11:52 am
Allogene Therapeutics: Q4 Earnings Snapshot - Mar 13th, 2025 8:11 pm
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - Mar 13th, 2025 8:02 pm
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - Mar 3rd, 2025 1:30 pm
Allogene Therapeutics Announces Participation in March Investor Conference - Feb 26th, 2025 1:30 pm
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia - Feb 25th, 2025 9:10 pm
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology - Feb 13th, 2025 9:30 pm
Allogene Therapeutics Announces Participation in February Investor Conferences - Feb 4th, 2025 1:30 pm
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - Jan 29th, 2025 4:34 pm
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer - Jan 29th, 2025 1:30 pm
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases - Jan 28th, 2025 1:30 pm
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Dec 26th, 2024 6:07 pm
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? - Dec 26th, 2024 5:00 pm
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Dec 24th, 2024 12:47 pm
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Dec 16th, 2024 1:30 pm
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - Dec 12th, 2024 1:30 pm
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - Dec 2nd, 2024 6:19 pm
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - Nov 25th, 2024 5:00 pm